TDC
FBIO icon

Thompson Davis & Co’s Fortress Biotech FBIO Stock Holding History

Thompson Davis & Co’s Portfolio FBIO Stock Details FBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-866
Closed -$3.77K – 119
2023
Q3 		$3.77K Hold
866
– – ﹤0.01% 109
2023
Q2 		$7.15K Hold
866
– – 0.01% 116
2023
Q1 		$10.7K Hold
866
– – 0.01% 101
2022
Q4 		$8.51K Hold
866
– – 0.01% 98
2022
Q3 		$11K Hold
866
– – 0.01% 84
2022
Q2 		$11K Hold
866
– – 0.02% 94
2022
Q1 		$18K Hold
866
– – 0.02% 99
2021
Q4 		$32K Buy
+866
New +$38.6K 0.03% 115

Other funds holding FBIO

CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
SAM
Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Thompson Davis & Co's FBIO Position: Q4 2023 in Review

Thompson Davis & Co sold out of Fortress Biotech (FBIO) in Q4 2023, closing a stake of 866 shares — an estimated $3.77K sold.

Thompson Davis & Co first reported a position in FBIO in Q4 2021 and held it in 8 quarters. The position peaked at $32K in Q4 2021. 42 funds tracked by Wall St. Rank hold FBIO as of Q4 2023.

  • Thompson Davis & Co reported no remaining Fortress Biotech position as of Q4 2023 after selling out during the quarter.
  • Thompson Davis & Co sold 866 Fortress Biotech shares in Q4 2023, an estimated $3.77K.
  • Thompson Davis & Co first reported a position in Fortress Biotech in Q4 2021 and held it in 8 quarters.
  • Thompson Davis & Co's Fortress Biotech position peaked at $32K in Q4 2021.
  • 42 funds tracked by Wall St. Rank held Fortress Biotech as of Q4 2023.

Based on Thompson Davis & Co's 13F filing for Q4 2023, filed 5 Feb 2024.